IDEXX Laboratories, Inc. $IDXX Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.1% during the first quarter, Holdings Channel.com reports. The firm owned 881,189 shares of the company’s stock after selling 87,757 shares during the period. Principal Financial Group Inc.’s holdings in IDEXX Laboratories were worth $495,164,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Chicago Partners Investment Group LLC grew its holdings in shares of IDEXX Laboratories by 19.0% during the first quarter. Chicago Partners Investment Group LLC now owns 1,157 shares of the company’s stock worth $669,000 after buying an additional 185 shares in the last quarter. Procyon Advisors LLC boosted its holdings in shares of IDEXX Laboratories by 13.5% during the first quarter. Procyon Advisors LLC now owns 3,296 shares of the company’s stock worth $1,852,000 after purchasing an additional 391 shares during the last quarter. LGT Fund Management Co Ltd. grew its position in shares of IDEXX Laboratories by 112.5% in the first quarter. LGT Fund Management Co Ltd. now owns 1,870 shares of the company’s stock valued at $1,051,000 after purchasing an additional 990 shares during the period. Arlington Capital Management Inc. grew its position in shares of IDEXX Laboratories by 4.8% in the first quarter. Arlington Capital Management Inc. now owns 479 shares of the company’s stock valued at $269,000 after purchasing an additional 22 shares during the period. Finally, Diversify Wealth Management LLC increased its stake in IDEXX Laboratories by 87.6% in the first quarter. Diversify Wealth Management LLC now owns 2,097 shares of the company’s stock valued at $1,161,000 after purchasing an additional 979 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 0.1%

IDXX opened at $564.21 on Tuesday. The firm’s 50 day moving average is $555.16 and its 200-day moving average is $602.92. IDEXX Laboratories, Inc. has a 52-week low of $506.91 and a 52-week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $44.50 billion, a P/E ratio of 41.55, a P/E/G ratio of 3.08 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on IDXX shares. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 25th. UBS Group dropped their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.